SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

This is a Phase I, single-center, single-arm, open-label clinical study to evaluate the safety, tolerability, and preliminary efficacy of SL4903 autologous T-cell injection (CAR-T cell therapy) in adult patients with relapsed or refractory multiple myeloma (r/r MM) who have failed prior standard therapies. The study employs a "3+3" dose-escalation design with three planned dose levels (1×10⁶, 2×10⁶, and 3×10⁶ CAR+ cells/kg). Approximately 9 to 18 evaluable subjects will be enrolled to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D), and to characterize the safety profile and potential anti-myeloma activity of SL4903.

NCT Number	NCT07234721
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China Collaborators: Hebei Senlang Biotechnology Inc., Ltd.
Conditions	Relapsed and Refractory Multiple Myeloma (RRMM)
Enrollment	9 participants
Start Date	2026-02-01
Primary Completion	2028-03-20 (estimated)
Study Completion	2028-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-10